Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Molly Harper Insider Profile
4 Followers
Molly Harper, Director at Catalyst Pharma, holds 0.00 shares in Catalyst Pharma (Ticker: CPRX). Most recently, Molly Harper Sold $5,333 shares of Catalyst Pharma on Jun 05, 2024 for an estimated value of 86.93K.
Profitable Transactions
0 out of 2 Profitable Transactions
Average Return
-9.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Molly Harper does not currently own shares as a corporate insider.
A breakdown of Molly Harper's holdings
Insider Roles
Director
Roles that Molly Harper holds in companies
Most Profitable Insider Trade
The most profitable trade made by Molly Harper
Molly Harper's Trading History
List of latest transactions for each holding click on a transaction to see Molly Harper's performance on stock
You May Also Like
Molly Harper insider profile FAQ
What is the percentage of profitable transactions made by Molly Harper?
The percentage of profitable transactions made by Molly Harper is 0%.
What is the average return per transaction made by Molly Harper?
The average return per transaction made by Molly Harper is -9.40%.
What stocks does Molly Harper hold?
Molly Harper holds: CPRX stocks.
What was Molly Harper’s latest transaction?
Molly Harper latest transaction was an Informative Sell of $86.93K.
What was Molly Harper's most profitable transaction?
Molly Harper’s most profitable transaction was an Informative Sell of CPRX stock on June 5, 2024. The return on the trade was -3.80%.
What is Molly Harper's role in Catalyst Pharma?
Molly Harper's role in Catalyst Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.